Drug Profile

Lomibuvir

Alternative Names: VCH-222; VX-222

Latest Information Update: 29 Jul 2016

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ViroChem Pharma
Developer Vertex Pharmaceuticals
Class Antivirals; Small molecules
Mechanism of Action Hepatitis C virus NS 5 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Hepatitis C

Most Recent Events

26 Jul 2016 Trek Therapeutics acquires lomibuvir from Vertex Pharmaceuticals
15 May 2014 Vertex Pharmaceuticals completes a phase II trial in Hepatitis C (treatment-naive, combination therapy) in USA, Canada, Germany, Poland and United Kingdom (NCT01516918)
01 Feb 2014 Vertex Pharmaceuticals terminates phase II ZENITH trial in Hepatitis C (treatment-naive, in combination with telapravir) in US and New Zealand (NCT01080222)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com